The top academic and corporate partners in the Nature Index

Exploring complementary strengths is the key to success in industry–academia science partnerships.

  • Mark Zastrow

Researchers in a laser laboratory at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland.

The top academic and corporate partners in the Nature Index

Exploring complementary strengths is the key to success in industry–academia science partnerships.

8 December 2017

Mark Zastrow


Researchers in a laser laboratory at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland.

Scientific collaborations between companies and universities are often most productive when the partners function as equals. When each side capitalizes on the sometimes contrasting strengths of the other to advance understanding of fundamental principles, the results can find their way into hospitals, schools and homes.

Here, we examine the top academic–industry partnerships as measured by their share of the authorship in papers appearing in the Nature Index from 2012 to 2016.


The University of Basel (UB) and the global headquarters of Novartis are a kilometre apart on the banks of the Rhine. But the key to their partnership lies on the other side of the river: the Friedrich Miescher Institute for Biomedical Research (FMI), an independent institution with longstanding ties to both the university and the pharmaceutical giant.

FMI was jointly founded as a basic research lab in 1970 by two of the three Basel-based drug companies, which eventually merged to form Novartis. Today, it receives roughly 70% of its funding from the Novartis Research Foundation and remains affiliated with the company’s in-house lab, the Novartis Institutes for Bio-Medical Research (NIBR). Students at FMI take courses and receive degrees at the University of Basel, where FMI group leaders also teach and advise students as adjunct faculty.

Its contribution is impressive: FMI researchers were co-authors on close to 90% of the 191 papers in the Nature Index from 2012 to 2016 with collaborations between Novartis and University of Basel-affiliated researchers.

Novartis reviews FMI’s research portfolio every year and has first right of refusal on any intellectual property. But FMI and its researchers set their own agenda, says molecular geneticist, Antoine Peters.

Peters is planning a project with researchers at the University Hospital Basel and other Swiss institutions to study people conceived by assisted reproductive technologies such as in vitro fertilization, and whether the vastly different environment from the womb affects genetic expression.

Susan Gasser, director of FMI, says that its existence should be taken as a measure of Novartis’ commitment to the Basel life sciences community, and to research “as a driver of innovation in the company, rather than buying in from biotech.”

Nature Index

Full size image


Novartis has more than 300 academic collaborations in its global research portfolio, according to a company spokesperson, which includes another trans-river pairing — between Harvard University's medical campus in Boston and NIBR’s global headquarters in Cambridge, across the Charles River. The pair of institutions has produced a steady stream of research, including 83 papers in the Nature Index from 2012 to 2016 — the third most prolific academic–industry partnership.

Collaborations with Harvard offer exposure to ideas from different fields, says Feng Cong, the director of the chemical biology and therapeutics department at NIBR’s global headquarters in Cambridge, Massachusetts. He works regularly with Marc Kirschner, a systems biologist at Harvard, who models biological systems with computer simulations.

Theirs is one of several collaborations between Novartis and labs at Harvard’s systems biology department, under an arrangement that Kirschner helped establish a decade ago, when he served on a Novartis advisory board. He says Novartis was not only looking for new drugs, but also took a serious interest in their basic research and methodologies. “They trusted that the scientists themselves would turn this into something of value.”

Novartis also works extensively with the Broad Institute, a partnership between Harvard and the Massachusetts Institute of Technology in Cambridge. The Broad Institute was the origin of a Harvard–Novartis collaboration examining how the Zika virus attacks the brain of developing fetuses. Scientists had suspected that it latched on to the surface of nerve cells via the protein AXL. But in a 2016 paper, Harvard and Novartis researchers working with brain organoids found that genetically disrupting AXL did not protect against the virus — evidently, it can take alternative routes into nerve cells.

The two Novartis hubs will soon be even more tightly linked: in 2016, Novartis announced it would concentrate more of its global research in Basel and Boston, including establishing a chemical biology and therapeutics team — using CRISPR and other cutting-edge technologies — to be jointly based in Basel and Cambridge, Massachusetts.


Samsung invested heavily in the technology, but the era of widespread graphene application is yet to occur.


Sungkyunkwan University (SKKU) and Samsung are more than research partners: in 1996, the conglomerate acquired the university. It’s not for nothing that South Koreans sometimes refer to SKKU — founded in 1398 as the highest institution of learning under the Joseon Dynasty — as Samsung University. Today, Samsung, which makes up 13% of the nation’s gross domestic product, reportedly invests 100 billion won (US$88.4 million) in the school every year.

Globally, there are examples of technical universities owned or operated by corporations, especially oil companies — Universiti Teknologi Petronas in Malaysia, owned by the nation’s national oil company; and the King Abdullah University of Science and Technology in Saudi Arabia, initially built and run by Saudi Aramco. And in Korea, the Pohang University of Science and Technology was originally founded by the steel company POSCO. But SKKU is unique for being a longstanding institution that sought to enter into such a far-reaching arrangement.

Ties between Samsung and SKKU date back to the 1960s, but the company’s 1996 acquisition was driven by Samsung’s desire to move into the medical field, and SKKU’s intent to open a medical school. The Samsung Medical Center opened in 1994 and became SKKU’s teaching hospital in 1997. Today, it is responsible for a significant portion of SKKU–Samsung research output in the Nature Index, along with materials and nanotechnology research. The two institutes have together published 105 papers in the journals included in the index over the past five years.

“Samsung has supported SKKU in many ways beyond research,” says Hong-Hee Won, a computational biologist at SKKU’s Samsung Advanced Institute of Health Sciences and Technology, located at Samsung Medical School’s campus in Seoul. Samsung’s funding for scholarships and new buildings, as well as the reputation of the brand itself, has attracted quality students to the university, he says.

Nature Index

Full size image

In return, Samsung is able to recruit graduates — researchers from its science and engineering schools, and managers from its business school — who have taken curricula tailored for the company’s needs. It also guides the university’s applied research agenda, creating entire institutes that align with its long-term strategic vision.

But what Samsung gives, Samsung can take away. This has been the case with graphene, the super-strong, conductive material that has long been of interest to Samsung’s electronics arm. In 2010, it set up a joint graphene research centre in the SKKU Advanced Institute of Nano Technology, with some university research groups receiving US$2 million per year.

In 2014, SKKU and Samsung researchers made headlines with a new production method that synthesizes graphene on top of a reusable layer of germanium, which guides the crystal growth to keep the structure uniform. The resulting graphene forms a single crystal big enough to be useful in electronics. The study was published in Science.

“We expect this discovery to accelerate the commercialization of graphene, which could unlock the next era of consumer electronic technology,” Samsung researchers said in a company statement at the time.

But that era has not yet materialized, as the company — and the rest of the world — struggles to find commercial applications for graphene.

Today, joint graphene research between SKKU and Samsung has all but ceased and the centre has been effectively discontinued, says one researcher with knowledge of the situation who asked not to be named. In the researcher’s opinion, Samsung “does not intend to industrialize graphene in the next one or two years.” Samsung continues to research the material at the Samsung Advanced Institute of Technology, an in-house lab in Suwon.


Tom Gilbert and Zhang Guojie at the Natural History Museum of Denmark in Copenhagen.


BGI’s ties to the University of Copenhagen (UCPH) started with a personal connection: one of the founders of the gene-sequencing company, Yang Huanming, received his PhD from UCPH in 1988.

Founded in 1999 as the Beijing Genomics Institute, in 2007 the organization moved to Shenzhen where it has grown to become one of the world’s premiere genomics institutes. Its ties to UCPH were cemented in 2012 when the university welcomed the opening of BGI-Europe on campus, a research centre with 10 Illumina sequencers. The two institutions have co-authored 127 papers in the index since 2012.The success of BGI’s commercial arm has given the firm a reputation in some quarters as a brute-force sequencing factory that relies on academic partners for knowledge. But BGI’s robust basic research division debunks that stereotype, says UCPH evolutionary biologist, Tom Gilbert.

In 2010, he teamed up with BGI’s Zhang Guojie to map the family tree of the modern bird. Zhang, also an evolutionary biologist, had already sequenced several species. Their effort snowballed into a collaboration of 200 scientists from 80 institutions around the world, sequencing 48 bird genomes, one from every major lineage, including the emperor penguin and the peregrine. It culminated in the near-simultaneous publication of 26 papers, including a special issue of Science in December 2014. Gilbert says it’s a big mistake to assume that BGI is merely a service provider in the partnership. “They weren’t just generating the genomes, they were driving a lot of the project.”

To Zhang, UCPH offers access to rich data, as well as its legacy of natural history research. Zhang moved to UCPH as a postdoctoral fellow during his collaboration with Gilbert. Now a full professor at UCPH, he says the university’s affiliation with the Natural History Museum of Denmark has offered the chance to tap into ancient DNA samples from a global network of museums. Zhang maintains an affiliation with BGI as an associate director of China National GeneBank, which BGI runs.

Denmark’s medical records, maintained in a unified database, are another good resource for BGI says Karsten Kristiansen, a genome scientist at UCPH and BGI advisor. In August, a consortium including UCPH and BGI published a reference genome for the Danish population derived from 150 people. The relationship will grow: the institutions established a joint PhD programme three years ago, offering longstanding BGI researchers the chance to earn a UCPH degree to go along with their research.

This story comes from Nature Index 2017 Science Inc., which investigates the changing role of corporate institutions in the world of science. See more stories here.